Drugs / IFN beta-1a
IFN beta-1a
also known as
Interferon beta-1a · FP-1201-lyo · IFN β-1a · Interferon (IFN) beta 1 a · IV IFN beta-1a
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04860518 | Aug 2021 → Apr 2022 | COVID-19 | Faron Pharmaceuticals Ltd | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03387046 Background | Mar 2018 → Jan 2019 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT01514370 Background | Apr 2012 → Mar 2016 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN beta-1a | “40 subjects with Interferon (IFN) beta 1 a 44 mcg TIW + Curcumin (BCM 95) and 40 subjects with IFN beta-1a 44 mcg TIW + placebo.” NCT01514370 ↗ |
| Known as | FP-1201-lyo | “investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a” NCT04860518 ↗ |
| Known as | IFN β-1a | “Primary endpoint was the efficacy of curcumin versus placebo as add-on therapy on new/enlarging T2 lesions in RMS subjects under treatment with subcutaneous IFN β-1a 44 mcg TIW.” PMID 34583214 ↗ Sep 2021 |
| Known as | Interferon (IFN) beta 1 a | “40 subjects with Interferon (IFN) beta 1 a 44 mcg TIW + Curcumin (BCM 95) and 40 subjects with IFN beta-1a 44 mcg TIW + placebo.” NCT01514370 ↗ |
| Known as | Interferon beta-1a | “investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a” NCT04860518 ↗1“Interferon beta 1a” NCT01514370 ↗ |
| Known as | IV IFN beta-1a | “investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a” NCT04860518 ↗ |
| Modality | Protein / enzyme biologic | “intravenous recombinant human Interferon beta-1a” NCT04860518 ↗ |
| Route | Subcutaneous | “Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.” NCT01514370 ↗ |